Von Hippel-Lindau (VHL) syndrome affects roughly 1 in 36,000 to 1 in 91,000 people, depending on the population studied. In the United States, the estimated prevalence is about 2.13 per 100,000 people, which translates to roughly 7,000 affected individuals nationwide. The condition does not favor one sex, ethnicity, or geographic region over another in any dramatic way, though subtle differences in how the disease manifests have been observed across populations.
How Common VHL Syndrome Is
VHL is a rare genetic condition, but it is one of the more well-characterized hereditary tumor syndromes. European studies have estimated prevalence rates ranging from about 1 in 39,000 to 1 in 91,000 people. In the U.S., claims-based data from 2019 put the figure at 2.13 cases per 100,000. Of those, roughly half had tumors in the brain or spinal cord, and a smaller subset had pancreatic tumors.
Because VHL often goes undiagnosed until a tumor is discovered, the true number of affected people is likely somewhat higher than insurance records suggest. Many carriers of the gene variant may not yet show symptoms, especially if they are young.
Who Inherits It
VHL follows an autosomal dominant inheritance pattern, meaning a child needs only one copy of the altered gene (from one parent) to be at risk. About 80% of people with VHL inherited the condition from an affected parent. The remaining 20% developed the condition from a new, spontaneous genetic change that occurred either in the egg or sperm that formed them, or very early in embryonic development. In some of these cases, a parent may carry the mutation in only some of their cells (a phenomenon called mosaicism) and never show symptoms themselves.
Each child of someone with VHL has a 50% chance of inheriting the altered gene. Because of this, first-degree relatives of anyone diagnosed with VHL are recommended to undergo genetic testing as part of their medical evaluation.
Age of Onset and Diagnosis
Most people with VHL first develop symptoms between ages 10 and 40, with the average age of presentation around 26. However, tumors can appear in childhood, which is why current consensus guidelines recommend that ocular screening begin within 12 months of birth for anyone known or suspected to carry the VHL gene variant. Eye exams are advised every 6 to 12 months until age 30, then at least yearly after that.
The specific age when problems appear can vary by tumor type and, possibly, by ethnicity. Data from an Indian cohort found that pancreatic tumors linked to VHL appeared at an average age of about 21, which is younger than what Western studies typically report. These differences may reflect genuine biological variation between populations, though they could also stem from differences in when and how patients are screened.
Sex Differences in Outcomes
VHL affects males and females at equal rates, but survival outcomes are not identical. A large study tracking patients over time estimated that men born in 2000 with VHL could expect to live to about 67, while women could expect to live to about 60. Women with VHL face a significantly higher risk of dying from a VHL-related cause, with roughly twice the risk compared to men after adjusting for other factors.
The reasons for this gap are not fully understood, but hormonal changes during pregnancy may play a role. Retinal tumors linked to VHL can grow or worsen during pregnancy, which is why screening is recommended before a planned pregnancy and every 6 to 12 months throughout it. Overall, though, survival for people with VHL has improved substantially over the decades as screening and treatment have advanced. About 79% of deaths in VHL patients are still related to the disease, but the proportion caused by kidney cancer specifically has dropped over time.
What the Disease Does to the Body
VHL causes tumors and cysts to grow in multiple organs. The specific combination varies from person to person, partly based on the type of genetic mutation involved. The disease is classified into two main types:
- Type 1 carries a low risk of adrenal gland tumors but a higher risk of kidney cancer, brain and spinal cord tumors, retinal tumors, and pancreatic cysts or tumors. It is typically caused by larger genetic deletions or mutations that severely disrupt the VHL protein.
- Type 2 carries a high risk of adrenal gland tumors and is subdivided further. Type 2A involves retinal and nervous system tumors but a low risk of kidney cancer. Type 2B includes all of those plus a high risk of kidney cancer. Type 2C produces only adrenal gland tumors. These subtypes are usually driven by smaller, more targeted genetic changes.
About 10% of people with VHL develop noncancerous tumors in the inner ear, which can cause hearing loss. Pancreatic cysts are common, appearing in over 60% of patients in some cohorts. The sheer variety of possible tumor locations is why VHL management involves coordinated care across multiple specialties, ideally at a center experienced with the condition.
Geographic and Ethnic Variation
VHL has been documented across every major ethnic group and geographic region. There is no population that is immune to it, nor one that is disproportionately burdened in a way comparable to conditions like sickle cell disease or Tay-Sachs. That said, researchers have identified subtle differences in how the disease presents across populations.
The types of underlying genetic mutations differ somewhat by region. In Asian populations, the small targeted mutations (called missense mutations) that are characteristic of Type 2 VHL are found in about 85% of Type 2 cases, compared to roughly 89% in European cohorts. Larger gene deletions are more common in Type 1 patients across all regions but occur at different rates: about 17% in pooled global data, but with variation between continents. These molecular differences can influence which organs are most at risk and at what age problems first appear.
Studies from India and Brazil have reported younger ages of diagnosis and different tumor profiles compared to Western European and North American data. Whether these reflect true biological differences, variations in healthcare access, or differences in study design remains an open question. What is clear is that VHL can affect anyone, regardless of background, and early genetic testing remains the most reliable way to identify at-risk individuals before tumors cause irreversible damage.